FMISO与FDG PET评估缺氧和糖代谢预测恶性胶质瘤IDH1突变及1p/19q共缺失状态
该回顾性研究纳入87例新诊断幕上恶性胶质瘤(WHO III-IV级)患者,术前行FMISO和FDG PET,分析摄取值与IDH突变及1p/19q共缺失的关系。结果显示FMISO TBR在IDH野生型中显著高于突变型,但判别准确性不满意;FDG TNR无法区分IDH状态;在WHO III级肿瘤中两者均不能预测IDH突变和1p/19q状态。
要点
- FMISO TBR在IDH野生型中显著高于突变型,但判别敏感性中等、特异性低。
- FDG TNR在IDH野生型与突变型间无统计学显著差异。
- WHO III级肿瘤中FMISO和FDG PET均不能预测IDH突变及1p/19q状态。
核心结论
- FMISO PET评估的肿瘤缺氧有助于预测新诊断恶性胶质瘤的IDH突变状态,但判别准确性不满意,不足以临床常规应用。
- FDG PET评估的糖代谢不能区分IDH突变状态。
- FMISO和FDG PET均不能预测WHO III级肿瘤的IDH突变和1p/19q共缺失状态。
研究设计与样本
- 回顾性分析87例新诊断幕上恶性(WHO III和IV级)胶质瘤患者,术前行FMISO和FDG PET。
- 根据2016 WHO分类用手术标本确定分子特征和组织病理诊断。
- FDG PET计算最大肿瘤/正常比值(TNR),FMISO PET计算最大肿瘤/血SUV比值(TBR),统计分析PET摄取值与IDH突变及1p/19q共缺失状态的关系。
主要发现
- 在所有肿瘤和恶性星形细胞瘤中,IDH野生型肿瘤的中位FMISO TBR显著高于IDH突变型(分别为P < 0.001和P < 0.01)。
- ROC分析中曲线下面积显示判别敏感性中等(0.7-0.8),特异性低(0.65-0.68)。
- 在同一人群中,IDH野生型肿瘤的中位FDG TNR倾向于高于IDH突变型,但差异无统计学意义。
- 在WHO III级间变性星形细胞瘤中,IDH突变型与野生型的中位FMISO TBR或FDG TNR无显著差异。
- 在IDH突变型WHO III级间变性胶质瘤中,间变性星形细胞瘤与间变性少突胶质细胞瘤的中位FMISO TBR或FDG TNR无显著差异。
关键数值与推荐
- FMISO TBR在IDH野生型与突变型比较:所有肿瘤P < 0.001,恶性星形细胞瘤P < 0.01。
- ROC曲线下面积判别敏感性中等(0.7-0.8),特异性低(0.65-0.68)。
临床怎么用
- FMISO PET可作为无创预测IDH突变状态的辅助参考,但判别准确性不满意,不能替代组织分子检测。
- FDG PET不推荐用于区分IDH突变状态。
- WHO III级肿瘤中不应依赖FMISO或FDG PET预测IDH突变和1p/19q共缺失状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor hypoxia and glycolysis have been recognized as determinant factors characterizing tumor aggressiveness in malignant gliomas. To clarify in vivo hypoxia and glucose metabolism in relation to isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status, we retrospectively analyzed hypoxia as assessed by positron emission tomography (PET) with [18F]-fluoromisonidazole (FMISO) and glucose metabolism as assessed by PET with [18F]-fluoro-2-deoxy-D-glucose (FDG) in newly diagnosed malignant gliomas. METHODS: In total, 87 patients with newly diagnosed supratentorial malignant (WHO grade III and IV) gliomas were enrolled in this study. They underwent PET studies with FMISO and FDG before surgery. The molecular features and histopathological diagnoses based on the 2016 WHO classification were determined using surgical specimens. Maximal tumor-to-normal ratio (TNR) was calculated for FDG PET, and maximal tumor-to-blood SUV ratio (TBR) was calculated for FMISO PET. The PET uptake values in relation to IDH mutation and 1p/19q codeletion status were statistically analyzed. RESULTS: In all tumors and malignant astrocytomas, the median FMISO TBR in IDH-wildtype tumors was significantly higher than that in IDH-mutant tumors (P < 0.001 and P < 0.01, respectively). In receiver operating characteristic (ROC) analysis, the area under the curve showed that the sensitivity for the discrimination was moderate (0.7-0.8) and the specificity was low (0.65-0.68). In the same population, the median FDG TNR in IDH-wildtype tumors tended to be higher than that in IDH-mutant tumors, but the difference was not statistically significant. In WHO grade III anaplastic astrocytomas, there were no significant differences in median FMISO TBR or FDG TNR between IDH-mutant and IDH-wildtype tumors. In IDH-mutant WHO grade III anaplastic gliomas, there were no significant differences in median FMISO TBR or FDG TNR between anaplastic astrocytomas and anaplastic oligodendrogliomas. CONCLUSIONS: Tumor hypoxia as assessed by FMISO PET was informative for prediction of the IDH mutation status in newly diagnosed malignant gliomas. However, the accuracy of the discrimination was not satisfactory for clinical application. On the other hand, glucose metabolism as assessed by FDG PET could not differentiate the IDH-mutant status. Moreover, PET studies using FMISO and FDG could not predict IDH mutation and 1p/19q codeletion status in WHO grade III tumors.
引用
- Suzuki K, Kawai N, Ogawa T, et al. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas. EJNMMI Res. 2021. PMID: 34291337. doi:10.1186/s13550-021-00806-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。